Researchers have created a device that can quickly and inexpensively determine whether new pharmaceutical formulations have trace crystallinity that can negatively impact the drug’s stability and bioavailability. The researchers have developed instrumentation that can accurately detect in early stages whether a pharmaceutical formulation has trace crystalline content. The instrument is based off of triboluminescence and works by measuring light emitted when a pharmaceutical powder is crushed.